ViroCyt Completes Second Close of Growth Capital Financing
(firmenpresse) - DENVER, CO -- (Marketwired) -- 04/03/13 -- , the leader in the field of rapid virus quantification, today announced the addition of new investors to its most recent round of funding. This financing was an extension of the initial close, which occurred on November 14, 2012, resulting in a total raise of approximately $5 million. Investors include High Country Venture and several experienced angel networks. The company's lead product is the Virus Counter® 2100, a technology created specifically to provide quantification of intact viral particles in minutes, avoiding the costs and delays associated with more traditional approaches.
"I have been extremely pleased by the enthusiastic response to our fund raising efforts. We were oversubscribed for the financing," said Robert Kline, the company's President and Chief Executive Officer. "The added capital will allow us to aggressively build upon the significant momentum we've seen develop during the past year for the Virus Counter system. We have recently added sales and technical personnel in the US, and will continue to expand our direct sales force as well as increase our network of international distributors in key regional markets. It's become clear that there is growing global demand for technologies like the Virus Counter that accelerate the process of creating life-saving products."
The primary application of the Virus Counter is in settings in which viruses are utilized directly as vaccines or to express proteins, which are subsequently used as therapies or vaccines. The Virus Counter can eliminate bottlenecks in critical development and manufacturing processes, replacing outdated viral quantification methods while delivering improved accuracy and significant cost savings.
ViroCyt was created with the goal of bringing game-changing solutions to the Life Science industry. Our primary focus is replacing outdated technologies that slow down the pace of virus-related research and product development. To learn more about ViroCyt, go to .
Michael Artinger
VP Marketing & Strategic Partnering
ViroCyt, LLC
+1-720-771-6670
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 03.04.2013 - 06:00 Uhr
Sprache: Deutsch
News-ID 1212876
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
DENVER, CO
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 73 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ViroCyt Completes Second Close of Growth Capital Financing
"
steht unter der journalistisch-redaktionellen Verantwortung von
ViroCyt (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
